Senti Biosciences Holdings, Inc. (SNTI)
| Market Cap | 11.02M -75.0% |
| Revenue (ttm) | 38,000 |
| Net Income | -51.55M |
| EPS | -1.86 |
| Shares Out | 31.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 134,463 |
| Open | 0.3664 |
| Previous Close | 0.3589 |
| Day's Range | 0.3331 - 0.3799 |
| 52-Week Range | 0.3331 - 2.8800 |
| Beta | 2.11 |
| Analysts | Buy |
| Price Target | 13.50 (+3,716.79%) |
| Earnings Date | Aug 14, 2026 |
About SNTI
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company’s lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SNTI stock is "Buy." The 12-month stock price target is $13.5, which is an increase of 3,716.79% from the latest price.
News
Senti Biosciences Holdings Proxy statement: Proxy filing
Senti Biosciences Holdings filed a proxy statement on July 21, 2026, providing details for shareholder voting and corporate governance matters.
Senti Biosciences Holdings Registration statement: Registration filing
Senti Biosciences Holdings filed a registration statement on July 16, 2026, providing details about a securities offering with the SEC.
Senti Bio announces transaction to spin off Gene-Circuit-enabled pipeline
Senti Bio (SNTI) announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial technology platform and unlock value fo...
Senti Biosciences Holdings Proxy statement: Proxy filing
Senti Biosciences Holdings filed a proxy statement on July 15, 2026, providing details for shareholder voting and corporate governance matters.
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its ...
Senti Biosciences Holdings Registration statement: Registration filing
Senti Biosciences Holdings filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
Senti Bio completes Type B RMAT meeting with FDA on SENTI-202
Senti Bio (SNTI) announced the successful completion of a Type B Initial Comprehensive Multidisciplinary Regenerative Medicine Advanced Therapy, or RMAT, meeting with the FDA regarding SENTI-202, the ...
Senti Biosciences Holdings Earnings release: Q1 2026
Senti Biosciences Holdings released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Senti Biosciences Holdings Quarterly report: Q1 2026
Senti Biosciences Holdings has published its Q1 2026 quarterly earnings report on May 14, 2026.
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory A...
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep a...
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Slides: Corporate presentation
Senti Biosciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 9, 2026.
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Annual report: Q4 2025
Senti Biosciences Holdings has published its Q4 2025 annual report on March 27, 2026.
Senti Biosciences Holdings Earnings release: Q4 2025
Senti Biosciences Holdings released its Q4 2025 earnings on March 27, 2026, summarizing the period's financial results.
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Transcript: Leerink Global Healthcare Conference 2026
Logic gating and gene circuits enable selective cancer cell targeting in AML, with SENTI-202 showing a 42% CR/CRh rate, strong safety, and rapid hematopoietic recovery in phase I. RMAT designation supports a single-arm registrational trial, and expansion into new indications and modalities is planned.
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene th...
Senti Biosciences Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Logic-gated cell therapy SENTI-202 showed high response rates and deep, durable remissions in relapsed/refractory AML, with a favorable safety profile and broad patient eligibility. Plans are underway for a pivotal trial and expansion into new indications, with strong physician and regulatory interest.
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene the...
Senti Bio completes enrollment in Phase 1 trial of SENTI-202
Senti Bio (SNTI)sciences announced the completion of enrollment in its Phase 1 clinical trial evaluating SENTI-202, a first-in-class CD33/FLT3-targeting Logic Gated CAR NK cell therapy, in patients wi...
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Robust SENTI-202 clinical data presented at ASH 2025 demonstrated deep, MRD-negative, durable complete remissions and a favorable safety profile Company planning for rapid advancement of SENTI-202 int...